Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Capital Leases (2016 - 2018)

Historic Capital Leases for Sangamo Therapeutics (SGMO) over the last 3 years, with Q4 2018 value amounting to $27.7 million.

  • Sangamo Therapeutics' Capital Leases rose 1192.9% to $27.7 million in Q4 2018 from the same period last year, while for Dec 2018 it was $27.7 million, marking a year-over-year increase of 1192.9%. This contributed to the annual value of $27.7 million for FY2018, which is 1192.9% up from last year.
  • Sangamo Therapeutics' Capital Leases amounted to $27.7 million in Q4 2018, which was up 1192.9% from $26.9 million recorded in Q3 2018.
  • Sangamo Therapeutics' Capital Leases' 5-year high stood at $27.7 million during Q4 2018, with a 5-year trough of $213000.0 in Q1 2016.
  • Moreover, its 3-year median value for Capital Leases was $3.9 million (2016), whereas its average is $12.4 million.
  • Per our database at Business Quant, Sangamo Therapeutics' Capital Leases surged by 174413.15% in 2017 and then skyrocketed by 1192.9% in 2018.
  • Sangamo Therapeutics' Capital Leases (Quarter) stood at $3.9 million in 2016, then surged by 527.07% to $24.7 million in 2017, then rose by 11.93% to $27.7 million in 2018.
  • Its Capital Leases stands at $27.7 million for Q4 2018, versus $26.9 million for Q3 2018 and $26.2 million for Q2 2018.